The deal could signal more M&A activity by Bay Area biotech companies, faced with a pullout by generalist investors and the need to cut costs, ditch programs or seek deals of some sort.
The deal could signal more M&A activity by Bay Area biotech companies, faced with a pullout by generalist investors and the need to cut costs, ditch programs or seek deals of some sort.
